Alagebrium Shows Potential in Diabetes-Related GI Complications
Posted on: Friday, 26 October 2007, 12:00 CDT
Synvista Therapeutics has published positive preclinical data demonstrating the ability of its compound, alagebrium, to reduce serum levels of advanced glycated end-products and restore neuronal nitric oxide synthase activity in rats with diabetes.
Loss of gastrointestinal neuronal nitric oxide synthase (nNOS) activity is one of the major putative mechanisms for the development of diabetic complications involving the gut, including gastroparesis and intestinal dysfunction and has been the subject of both intense investigation and thorough review.
Diabetic gastroparesis is a motility disorder in which the stomach takes too long to empty its contents. It is a disease of significant unmet medical need, as no pharmaceutical products are approved for the treatment of this condition.
Patients with diabetes commonly experience gastric and intestinal dysfunction, however, the mechanism of how this happens is not well understood. The term diabetic enteropathy is often used to explain the disturbance in bowel function such as chronic diarrhea which occurs in 15% or more diabetics. A role for decreased nNOS expression has been suggested as a possible cause for the diarrhea; however, how diabetes causes such changes in nNOS expression levels is unknown.
Source: Datamonitor
Related Articles
- Pipex Pharmaceuticals Executes Option to License Oral Flupirtine Patent Estate for Diabetes, Diabetic Retinopathy, Retinitis Pigmentosa and Glaucoma
- A Path to a Diabetes Cure?
- Vegetarian Diet Can Help Combat Diabetes
- Diabetes in Pets: Signs, Treatments
- Diabetes: Facts, Tips and Trivia About the Disease
- No Sugar Babies
- The Cause of Your Condition
- Know the Insulin Facts
- Diagnosis and Classification of Diabetes Mellitus
- Tackle Childhood Obesity, Stop Diabetic Timebomb
 |
 |
User Comments (0)
RSS Feeds